Lipoprotein associated phospholipase A 2 , inhibitors...

Details Lipoprotein associated phospholipase A 2 , inhibitors... Lipoprotein associated phospholipase A 2 , inhibitors...

2006-05-30

2006-05-30

Nolan, Patrick J. (Department: 1644)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving hydrolase

C435S004000

Reexamination Certificate

active

07052862

ABSTRACT:
The enzyme Lp-PLA2in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2in therapy and a method of screening compunds to identify those compounds.

REFERENCES:
patent: 5019508 (1991-05-01), Johnson et al.
patent: 5108899 (1992-04-01), Allen
patent: 5210017 (1993-05-01), Carlsson et al.
patent: 5279957 (1994-01-01), Gross
patent: 5527698 (1996-06-01), Knopf et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5532152 (1996-07-01), Cousens et al.
patent: 5605801 (1997-02-01), Cousens et al.
patent: 5641669 (1997-06-01), Cousens et al.
patent: 5656431 (1997-08-01), Cousens et al.
patent: 5698403 (1997-12-01), Cousens et al.
patent: 5847088 (1998-12-01), Cousens et al.
patent: 5880273 (1999-03-01), Adachi et al.
patent: 5968818 (1999-10-01), Gloger et al.
patent: 5977308 (1999-11-01), Cousens et al.
patent: 5981252 (1999-11-01), MacPhee et al.
patent: 6045794 (2000-04-01), Cousens et al.
patent: 6099836 (2000-08-01), Cousens et al.
patent: 6146625 (2000-11-01), Cousens et al.
patent: 6177257 (2001-01-01), MacPhee et al.
patent: 6203790 (2001-03-01), Cousens et al.
patent: 359425 (1989-08-01), None
patent: 509719 (1992-10-01), None
patent: 658205 (2000-03-01), None
patent: 673426 (2001-06-01), None
patent: 04346797 (1988-08-01), None
patent: 07059597 (1989-10-01), None
patent: WO 89/09818 (1989-10-01), None
patent: WO 94/20069 (1994-09-01), None
patent: WO 95/00649 (1995-01-01), None
patent: WO 95/09921 (1995-04-01), None
patent: WO 97/12984 (1997-04-01), None
patent: WO 98/44158 (1998-10-01), None
patent: WO 99/09147 (1999-02-01), None
patent: WO 99/64627 (1999-12-01), None
patent: WO 00/24910 (2000-05-01), None
patent: WO 00/32808 (2000-06-01), None
Cornell University of Medicine Web site, 2005, Cerebrovascular Diseases.
Campbell, Biology, 3rdEdition, 1993.
Yamamoto et al. (1990) Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein. Oxid. Damage Repair, In. Soc. Free Radical Res. Bienn. Meeting. Meeting Date 1990, pp. 287-291. Editor: K.J.A. Da, Jan. 1990.
Kim Ut, et al. “Synthesis of Phospholipid Head groups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes,” J. Chem. Commun.: 70-71 (1993).
Christoffersen R, et al. “Ribozymes as Human Theraputic Agents,” J. of Medicinal Chem.: 2023-2037 (1994).
Stull R, et al., “Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects,” Pharm. Res. 1995.
Kohler G, et al., Nature 256:495-497 (1975).
Kuby, Immunology, 1991, W. H. Freeman, pp. 80-83.
Stafforini et al., “Platelet-activating Factor Acetohydrolyases”, J. Biol. Chem. 272(29):17895-17898 (1997).
Hirashima et al., Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage, J. Neurosurg 1994 80:31-36.
Satoh et al., Platelet-Activating Factor Acetylhydrolase in Plasma Lipoproteins From Patients With Ischemic Stroke, Stroke 1992 23:1090-1092.
Satoh et al., “Activity of Platelet-Activating Factor (PAF) Acetylhydrolase in Plasma From Patients With Ischemic Cerebrovascular Disease”, Prostaglandins 1988 35 (5):685-698.
Yoshida et al., “Platelet-activating factor acetylhydrolase activity in red blood cell-stroma from patients with cerebral thrombosis”, Acta Neurol Scand 1992 86:199-203.
Washburn, W.N. and Dennis, E.A. “Novel General Approach for the Assay and Inhibition of Hydrolytic Enzymes Utilizing Suicide-Inhibitory Bifunctional Linked substrates (SIBLINKS):Exemplified in a Phospholipase Assay” J. Am. Chem. Soc. 1990 112:2040-2041.
Washburn, W.N. and Dennis, E.A. “Suicide-inhibitory Bifunctionally Linked Substrates (SIBLINKS) as Phospholipase A2 Inhibitors” J. Biol. Chem. 1991 266(8):5042-5048.
Adjei et al., “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers”, Pharm. Res. 7(6):565-569 (1990).
Basran et al., “Properties of Platelet Activating Factor (PAC-ACETHER) Which Suggest Involvement in Chronic Inflammation and Persistent Asthma”, Br. J. Pharmacol. 77:437 (1982).
Braquet et al., “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig”, J. Cardio. Pharm. 13 (Supp.5):S143-S146 (1989).
Brenner, “The Molecular Evolution of Genes and Proteins: A Tale of Two Serines”, Nature 334:528-530 (1988).
Campbell, Biology 3rd Ed., p. 104-106 (1993).
Capecchi, “Altering the Genome by Homologous Recombination”, Science 244:1288-1292 (1989).
Caplan et al., “Role of Platelet Activating Factor and Tumor Necrosis Factor-alpha in Neonatal Necrotizing Entercolitis”, J. Pediatr. 116(6):960-964 (1990).
Chapus et al., “Minireview on Pancreatic Lipase and Colipase”, Blochimie 70:1223-1234 (1988).
deBoer et al., “The tac Promoter: A Functional Hybrid Derived from the trp and lac Promoters”, Proc. Natl. Acad. Sci. USA 80:21-25 (1983).
Debs et al., “Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats”, J. Immunol. 140(10):3482-3488 (1988).
Denizot et al., “PAF-Acether and Acetylhydrolase in Stool of Patients with Crohn's Disease”, Digestive Diseases and Sciences 37(3):432-437 (1992).
Furukawa et al., “Platelet-activating Factor-induced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase”, Ped. Res. 34(2):237-241 (1993).
Grino et al., “BN 52021:A Platelet Activating Factor Antagonist for Preventing Post-Transplant Renal Failure”, Ann. Int. Med. 121(5):345-347 (1994).
Hahn et al., “The Complete Sequences of Plasmids pFNeo and pMH-Neo: Convenient Expression Vectors for High-level Expression of Eukaryotic Genes in Hematopoietic Cell Lines”, Gene 127:267-268 (1993).
Harlow et al., “Antibodies: A Laboratory Manual”, Cold Spring Harbor Press, p. 423 (1988).
Handley et al., “Platelet Activating Factor and Inflammation in Atherogenesis: Targets for Drug Development”, Drug Dev. Res. 7:361-375 (1986).
Hattori et al., “The Catalytic Subunit of Bovine Brain Platelet-activating Factor Acetylhydrolase is a Novel Type of Serine Esterase”, J. Biol. Chem. 269(37):23150-23155 (1994).
Hattori et al., “Purification and Characterization of Bovine Brain Platelet-activating Factor Acetylhydrolase”, J. Biol. Chem. 268(25):18748-18753 (1993).
Henriques et al., “Endothelin-1 Inhibits PAF-induced Paw Oedema and Pleurisy in the Mouse”, Br. J. Pharmacol. 106:579-582 (1992).
Heuer et al., “Current Status of PAF Antagonists”, Clin. Exp. Allergy 22:980-983 (1992).
Hoffman et al., “Detection of Platelet-activating Factor in Amniotic Fluid of Complicated Pregnancies”, Am. J. Obstet Gynecol. 162(2):525-528 (1990).
Horwitz et al., “DNA Sequences of the araBAD-araC Controlling Region inSalmonella typhimuriumLT2”, Gene 14:309-319 (1981).
Hsieh et al., “Increased Plasma Platelet-activating Factor in Children with Acute Asthmatic Attacks and Decreased in vivo and in vitro Production of Platelet-activating Factor After Immunotherapy”, J. Allergy Clin. Immunol. 91:650-657 (1993).
Hsueh et al., “Platelet-activating Factor, Tumor Necrosis Factor, Hypoxia and Necrotizing Enterocolitis”, Acta Paediatr. Suppl. 396:11-17 (1994).
Hubbard et al., “Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract in alpha1-Antitrypsin Deficiency Directly Augmented with an Aerosol of A-1-Antitrypsin”, Ann. Int. Med. 111(3):206-212 (1989).
Kald et al., “Release of Platelet-Activating Factor in Acute Experimental Pancreatis”, Pancreas 8(4):440-442 (1993).
Kirsch et al., “Mechanism of Platelet Activating Factor-Induced Vascular Leakage in the Rat Trachea”, Exp. Lung Res. 18:447-459 (1992).
Kur

Affiliated with

Also associated with

Rating

Lipoprotein associated phospholipase A 2 , inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipoprotein associated phospholipase A 2 , inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein associated phospholipase A 2 , inhibitors... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3596350